Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Mobarak S (DISCOVER)
 
IRCT20200624047908N
RCTsofosbuvir and daclatasvirplaceboCOVID 19 hospitalizedsome concern
541/542 inconclusive
  • inconclusive 3 % decrease in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
Sadeghi
 
IRCT20200128046294N2
RCTsofosbuvir and daclatasvirstandard of careCOVID 19 hospitalizedsome concern
35/35 suggested
  • suggested 2.6-fold increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Yakoot
 
DRKS00022203
RCTsofosbuvir and daclatasvirstandard of careCOVID 19 hospitalizedsome concern
44/45 suggested
  • suggested 60 % increase in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
2 studies excluded by filtering options (1 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).